[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100331417":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":30,"responsibleParty":64,"collaborators":68,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":19,"eligibilityCriteria":77,"healthyVolunteers":73,"sex":78,"minAge":19,"maxAge":19,"enrollmentInfo":79,"targetDuration":19,"studyType":82,"phases":83,"briefSummary":86,"conditions":87,"keywords":19,"overallStatus":33,"whyStopped":19,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Children's National Research Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"CMV\u002FAdV \u002FEBV\u002FBKV specific T cells","EXPERIMENTAL","CMV\u002FAdV \u002FEBV\u002FBKV specific T cells will be thawed and transferred to a syringe given by slow intravenous injection over 1-2 minutes. Three dose levels will be explored. The lowest dose level will be 1x107cells\u002Fm2 and the highest will be 5x107\u002Fm2.",[13],"Biological: CMV\u002FAdV \u002FEBV\u002FBKV specific T cells",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"BIOLOGICAL","Each cohort of 2 patients will be treated and observed for 45 days for toxicity, dose escalation, and GvHD. The algorithm of sequentially adaptive EffTox trade-off-based design of Thall et al will be used to determine the dose for each cohort. If 1x107CTL\u002Fm2 results in unacceptable toxicity or efficacy, the study will be closed to accrual.",[9],null,[21,26],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Allistair Abraham, MD","CONTACT","202-476-5772","AAbraham@childrensnational.org",{"name":27,"role":23,"phone":28,"phoneExt":19,"email":29},"Fahmida Hoq, MBBS, MS","202-476-334","fhoq@childrensnational.org",[31,50],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Children's National Health System","RECRUITING","Washington D.C.","District of Columbia","20010","United States","US",{"type":40,"coordinates":41},"Point",[42,43],-77.03637,38.89511,{"lat":43,"lon":42},[46,48],{"name":27,"role":23,"phone":47,"phoneExt":19,"email":29},"202-476-3634",{"name":22,"role":49,"phone":19,"phoneExt":19,"email":19},"PRINCIPAL_INVESTIGATOR",{"facility":51,"status":33,"city":52,"state":53,"zip":54,"country":37,"countryCode":38,"cosmosGeoPoint":55,"geoPoint":59,"contacts":60},"M.D. Anderson Cancer Center (MDACC)","Houston","Texas","77030",{"type":40,"coordinates":56},[57,58],-95.36327,29.76328,{"lat":58,"lon":57},[61,63],{"name":62,"role":23,"phone":19,"phoneExt":19,"email":19},"Amanda Olson, MD",{"name":62,"role":49,"phone":19,"phoneExt":19,"email":19},{"type":65,"investigatorFullName":66,"investigatorTitle":67,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"SPONSOR_INVESTIGATOR","Catherine Bollard","Director, Center for Cancer and Immunology\u002F Center for Emerging Technologies in Immune Cell Therapies (CETI)",[69],{"name":70,"class":6},"M.D. Anderson Cancer Center","100331417","phase-1-adoptive-cord-blood-immunotherapy-for-ebv-cmv-bkv-and-adenovirus-reactivationinfection-or-prophylaxis-100331417",false,"NCT03594981","Adoptive Cord Blood Immunotherapy for EBV, CMV, BKV and Adenovirus Reactivation\u002FInfection or Prophylaxis","Adoptive Cord Blood ImmunotHerapy Using Expanded Cord Blood T Cells for EBV, CMV, BKV and Adenovirus Reactivation\u002FInfection or ProphylaxiS","Inclusion Criteria:\n\nInclusion Criteria at the Time of Procurement\n\n* Pediatric and adult patients (there are no lower and upper age limits for patients) with malignant or nonmalignant diseases who are candidates for transplant.\n* Patients must have a CB unit (or units) matched with the patient at 4, 5, or 6\u002F6 HLA class I (serological) and II (molecular) antigens. The unit selected for CTL expansion must be either:\n\n  1. be cryopreserved in two fractions, with a minimum of 2.5x107 total nucleated cells (TNC) per kg pre-thaw in the fraction which will be used for the primary transplant. The remaining fraction will be used to generate the CTLs to give at day 30 or beyond as described below. OR\n  2. be cryopreserved with a cell dose that totals \\> 3x10e7 TNC per kg pre thaw. On thaw, 20% of the total volume will be used for CTL manufacture to give at day 30 or beyond and the remaining 80% will be used for the primary transplant.\n  3. For recipients of double CBT, if possible both CB units should be cryopreserved in two fractions and T-cells will be made from both units if possible.\n\nInclusion Criteria at the Time of CTL Infusion\n\n* Recipients of at least one unmanipulated cord blood unit as described above (i.e. from a HLA matched or mismatched unrelated donor) transplant at risk for or with CMV\u002FAdenoviral\u002FBKV and\u002For EBV infection or reactivation.\n* Lansky\u002FKarnofsky scores ≥60\n* Absolute neutrophil count (ANC) greater than 500\u002Fu\n* No evidence of GVHD \\> Grade II at time of enrollment\n* Life expectancy \\> 30 days\n* Absence of severe renal disease (Creatinine \\\u003C 3x normal for age)\n* Absence of severe hepatic disease. Direct bilirubin must be \\\u003C 3 mg\u002Fdl and AST \\\u003C 5x upper limit of normal\n* Patient must be at least 30 days post transplant to be eligible to receive CTL\n* Written informed consent and\u002For signed assent line from patient, parent or guardian\n\nExclusion Criteria:\n\nExclusion Criteria at the Time of Procurement\n\n* Pregnant or lactating\n* Patients with active central nervous system disease\n* Patients with Karnofsky performance status \\\u003C70%\n* Patients with grade 3 or 4 or primary myelofibrosis\n* Patients with suitable related donors Exclusion Criteria at the Time of CTL Infusion\n* Pregnant or lactating\n* Patient on Fi02 of \\>60%\n* Unable to wean steroids to ≤0.5 mg\u002Fkg\u002Fday prednisone or equivalent\n* Patients with Grade 3 hyperbilirubinemia\n* Patients with other uncontrolled infections (except CMV and\u002For adenovirus and\u002For EBVemia and\u002For BK viruria\u002Fviremia). For bacterial infections, patients must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to enrollment. For fungal infections patients must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to enrollment. Progressing infection is defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection.\n* Patients with less than 50% donor chimerism in either peripheral blood or bone marrow or patients with relapse of original disease\n* Patients who have received investigational (IND) product within 28 days of screening for CTL infusion under this study","ALL",{"count":80,"type":81},36,"ESTIMATED","INTERVENTIONAL",[84,85],"PHASE1","PHASE2","This Phase I-II dose-finding trial to determine the optimal dose of intravenous (IV) injection dose of donor-derived cytotoxic T lymphocytes (CTLs) specific for CMV, EBV, BKV and Adenovirus. A maximum of 36 patients will be treated in up to 18 cohorts each of size 2, with the first cohort treated at the lowest dose level 1, all successive doses chosen by the EffTox method, and no untried dose level skipped when escalating.\n\nThe scientific goal of the trial is to determine an optimal IV-CTL cell dose level among the three doses 1.0x107cells\u002Fm2, 2 x107cells\u002Fm2 and 5x107cells\u002Fm2., hereafter dose levels 1, 2, 3. Dose-finding will be done using the sequentially adaptive EffTox trade-off-based design of Thall et al.",[88],"Viral Infection","2024-08-27",{"date":91,"type":92},"2024-08-28","ACTUAL",{"date":94,"type":92},"2018-01-24",{"date":96,"type":81},"2025-11",{"name":66,"class":6},2]